United States: FDA Issues Draft Guidance On Postmarket Cybersecurity Of Medical Devices

On January 15, 2016, the Food and Drug Administration ("FDA") released a draft guidance entitled, "Postmarket Management of Cybersecurity in Medical Devices," outlining recommendations that device manufacturers should implement to manage postmarket cybersecurity vulnerabilities. The draft guidance sets forth considerations for assessing and addressing postmarket cybersecurity vulnerabilities, which are continually evolving and not possible for device manufacturers to mitigate solely through premarket controls. The draft guidance also emphasizes that an effective cybersecurity risk management program should cover the premarket and postmarket lifecycle phases, and reminds industry of the recommendations set forth in FDA's 2014 guidance on "Content of Premarket Submissions for Management of Cybersecurity in Medical Devices," discussed in a previous Ropes & Gray Alert.

Device manufacturers should review this draft guidance document closely and consider its implications for the postmarket monitoring of their current products. The comment period will remain open for 90 days.

Government Initiatives to Address Cybersecurity Vulnerabilities

The cybersecurity postmarket draft guidance, together with the 2014 premarket guidance, are elements of a larger government initiative to strengthen the nation's cybersecurity systems. In February 2013, the President issued Executive Order 13636 and Presidential Policy Directive 21, which recognize that public and private stakeholders must enhance the cybersecurity and resilience of the nation's critical infrastructure, including within the healthcare and public health sector. Executive Order 13636 also called for the National Institute of Standards and Technology ("NIST") to develop a framework intended to reduce cybersecurity risks to critical infrastructure. The first version of the NIST's framework, released in February 2014, provides a structure that the draft guidance recommends device manufacturers use and adopt, outlining the elements of a cybersecurity risk management program (i.e., identify, protect, detect, respond, and recover). FDA's draft guidance incorporates several key principles of the NIST's framework, as described further below.

In addition, on February 13, 2015, the President issued Executive Order 13691, which encourages the development of Information Sharing Analysis Organizations (ISAOs) to serve as focal points for cybersecurity information sharing and collaboration within the private sector as well as between the private sector and the government. The draft guidance strongly recommends that device manufacturers voluntarily participate in an ISAO as part of a comprehensive proactive approach to managing postmarket cybersecurity threats and vulnerabilities, and to assuring the continued safety and effectiveness of marketed medical devices.

FDA's Recommendations on Postmarket Cybersecurity Management

The draft guidance outlines recommendations for the monitoring, identification, and remediation of postmarket cybersecurity vulnerabilities and exploits. According to the draft guidance, manufacturers' postmarket cybersecurity risk management programs should be implemented as part of the Quality System Regulation (21 C.F.R. Part 820), covering several QSR elements, including complaint handling (21 C.F.R. § 820.198), quality audit (21 C.F.R. § 820.22), corrective and preventive action (21 C.F.R. § 820.100), software validation and risk analysis (21 C.F.R. § 820.30(g)), and servicing (21 C.F.R. § 820.200).

I. Principles of a Postmarket Cybersecurity Management Program

According to the draft guidance, a postmarket cybersecurity risk management program should address vulnerabilities that may permit the unauthorized access, modification, misuse or denial of use of a device, or the unauthorized use of information that is stored, accessed, or transferred from a medical device to an external recipient, and that may impact patient safety. The critical components of such a program should include:

  • monitoring cybersecurity information sources for identification and detection of cybersecurity vulnerabilities;
  • understanding, assessing, and detecting vulnerabilities;
  • establishing processes for vulnerability intake and handling;
  • defining essential clinical performance to develop mitigations that protect and recover from cybersecurity risks;
  • adopting a coordinated vulnerability disclosure policy and practice; and
  • deploying mitigations that address cybersecurity risks prior to exploitation.

II. Evaluation of Risk to Essential Clinical Performance

The draft guidance explains that not all cybersecurity vulnerabilities present patient safety concerns. Rather, medical device manufacturers should assess the impact of the vulnerability on the "essential clinical performance" of the device, defined as the performance necessary to achieve freedom from unacceptable clinical risk. The draft guidance recommends that device manufacturers define, as part of the postmarket cybersecurity risk management, the essential clinical performance of the device, the resulting severity outcomes if compromised, and the risk acceptance criteria. FDA also recommends that device manufacturers measure the risk to the device's essential clinical performance by considering (i) the exploitability of the cybersecurity vulnerability and (ii) the severity of the potential health impact.

III. Remediating and Reporting Cybersecurity Vulnerabilities

FDA encourages efficient, timely, and ongoing cybersecurity risk management for marketed devices. To this end, the draft guidance states that FDA will not typically require premarket review to clear or approve software updates and patches intended to improve cybersecurity. Similarly, the draft guidance states that changes to strengthen cybersecurity will typically be considered device enhancements that are not required to be reported as removals or corrections under 21 C.F.R. Part 806, unless the cybersecurity vulnerabilities may compromise the essential clinical performance of the device and present a reasonable probability of serious adverse health consequences or death. If the device is approved under a PMA, the manufacturer must submit periodic reports to FDA, which may include newly acquired information concerning cybersecurity vulnerabilities and device changes made as part of cybersecurity updates and patches.

The draft guidance also announces an enforcement discretion policy for changes or other actions to address uncontrolled risks to essential clinical performance. Under this policy, FDA does not intend to enforce reporting requirements under 21 C.F.R. Part 806 if (i) there are no known serious adverse events or deaths associated with the vulnerability, (ii) within 30 days of learning of the vulnerability, the manufacturer identifies and implements device changes and/or compensating controls to bring the residual risk to an acceptable level and notifies users, and (iii) the manufacturer is a participating member of an ISAO.

FDA explains that, in the absence of remediation, a device with uncontrolled risk to its essential clinical performance may be subject to mandatory recall or other agency action.

Consequences for Medical Device Manufacturers

Although FDA's cybersecurity efforts are relatively new, it is by now clear that this is an area of significant and increased FDA focus. Device manufacturers that have not already done so should be carefully assessing and addressing potential cybersecurity vulnerabilities over the lifecycle of their devices. Manufacturers should exercise vigilance in monitoring postmarket cybersecurity information from all sources, assessing identified risks, and appropriately responding to vulnerabilities.

The release of FDA's draft guidance coincides with FDA's public workshop on January 20-21, 2016, to highlight past collaborative efforts, increase awareness of existing maturity models used to evaluate cybersecurity status, standards, and tools, and to identify unresolved gaps and challenges in the progress of medical device cybersecurity. Through the public workshop, FDA is seeking broad public input on strategies for addressing the medical device cybersecurity within the complex medical device ecosystem.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions